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ALIX/AIP1 functions in enveloped virus bud-
ding, endosomal protein sorting, and many
other cellular processes. Retroviruses, includ-
ing HIV-1, SIV, and EIAV, bind and recruit ALIX
through YPXnL late-domain motifs (X = any res-
idue; n = 1–3). Crystal structures reveal that hu-
man ALIX is composed of an N-terminal Bro1
domain and a central domain that is composed
of two extended three-helix bundles that form
elongated arms that fold back into a ‘‘V.’’ The
structures also reveal conformational flexibility
in the arms that suggests that the V domain
may act as a flexible hinge in response to ligand
binding. YPXnL late domains bind in a con-
served hydrophobic pocket on the second
arm near the apex of the V, whereas CHMP4/
ESCRT-III proteins bind a conserved hydropho-
bic patch on the Bro1 domain, and both interac-
tions are required for virus budding. ALIX there-
fore serves as a flexible, extended scaffold that
connects retroviral Gag proteins to ESCRT-III
and other cellular-budding machinery.
INTRODUCTION
Many enveloped RNA viruses use short peptide motifs,
termed ‘‘late domains,’’ to recruit cellular factors that facil-
itate budding (reviewed in Bieniasz, 2006; Demirov and
Freed, 2004; Morita and Sundquist, 2004). Two of the
best characterized late domains are the PTAP motif, which
binds and recruits TSG101 (tumor susceptibility gene 101;
Demirov et al., 2002; Garrus et al., 2001; Gottlinger et al.,
1991; Huang et al., 1995; Martin-Serrano et al., 2001; Ver-
Plank et al., 2001), and the YPXnL motif (where X can vary
in sequence and length), which binds ALIX/AIP1 (ALG-2-
interacting protein X; Chen et al., 2005; Puffer et al.,
1997; Strack et al., 2003; Vincent et al., 2003). YPXnLlate domains can vary in sequence and can function alone
or together with PTAP late domains. For example, the
structural p6Gag protein of HIV-1NL4-3 contains 7PTAP10
and 36YPLASL41 late domains that function in tandem,
whereas the analogous EIAV p9Gag protein contains a sin-
gle 23YPDL26 late domain. In principle, multiple late do-
mains could synergistically enhance virus release and/or
expand viral tropism.
Both TSG101 (Vps23p in yeast) and ALIX (Bro1p) help
sort membrane proteins into vesicles that bud into the lu-
men of multivesicular bodies (MVB), which supports the
idea that virus budding and MVB vesicle formation are
highly related processes. The requirements for MVB pro-
tein sorting and vesicle formation are best understood in
yeast, where the process requires the action of at least
18 different ‘‘Class E’’ proteins. Most, but not all, Class E
proteins are stable subunits of the three ESCRT com-
plexes (endosomal sorting complexes required for trans-
port; Hurley and Emr, 2006). Humans have at least one ho-
molog of every yeast Class E protein, and MVB vesicle
sorting therefore appears to be a highly conserved pro-
cess, albeit one that occurs with considerably greater
complexity in mammals.
TSG101 functions as the central subunit of ESCRT-I,
which recognizes ubiquitylated membrane-protein
cargoes and helps recruit the downstream machinery nec-
essary for protein sorting and MVB vesicle formation (Hur-
ley and Emr, 2006). This downstream machinery includes
the ESCRT-III and VPS4-LIP5 complexes, which appear
to be intimately involved in the actual mechanics of protein
sorting and vesicle formation. ALIX is also a Class E protein
and can interact directly with both ESCRT-I and ESCRT-III
but is not a stable subunit of either complex (reviewed in
Odorizzi, 2006). The yeast homolog Bro1p also recruits
the deubiquitylating enzyme Doa4p, which removes ubiq-
uitin from cargoes as they are sorted into MVB vesicles
(Dejournett et al., 2006; Luhtala and Odorizzi, 2004).
In addition to its roles in virus budding and MVB cargo
sorting, ALIX has also been implicated in a number of other
important cellular processes, including (1) MVB vesicle fis-
sion and back fusion via regulation of the conical lipid,Cell 128, 841–852, March 9, 2007 ª2007 Elsevier Inc. 841
lysobisphosphatidic acid (LBPA; reviewed in van der Goot
and Gruenberg, 2006); (2) endocytosis via interactions
with the membrane-curvature-sensing endophilins (Cha-
tellard-Causse et al., 2002; Gallop and McMahon, 2005);
(3) cell-surface-receptor downregulation via direct inter-
actions with cell-surface receptors (Geminard et al.,
2004) and through antagonism of the Cbl-SETA/CIN85-
endophilin complex (Schmidt et al., 2004); (4) spatial distri-
bution of endosomes via regulation of cortical actin (Cabe-
zas et al., 2005); (5) cell motility/adhesion via interactions
with FAK (focal adhesion kinase), PYK2 (proline-rich
tyrosine kinase 2; Schmidt et al., 2003), and possibly also
RabGAPLP (Rab GTPase-activating protein-like protein;
Ichioka et al., 2005); (6) apoptosis via interactions with the
calcium-binding EF-hand protein ALG-2 (apoptosis-linked
gene-2; reviewed in Sadoul, 2006); (7) regulation of the
JNK signaling pathway via interactions with ALG-2 and
the ubiquitin E3 ligase POSH (plentyofSH3 domains; Tsuda
et al., 2006). The latter observation is of particular interest
because POSH is also required for HIV-1 release (Alroy
et al., 2005), which raises the possibility that the ALIX-
POSH-ALG-2 complex could function in HIV-1 budding.
In summary, it is now apparent that ALIX performs a se-
ries of important functions in the endosomal pathway, in
cytoskeletal dynamics, and in enveloped virus budding.
However, the mechanistic bases for these seemingly di-
verse ALIX functions are not known. Our studies were
therefore undertaken with the goals of elucidating the
structure of ALIX, determining how it interacts with retrovi-
ral Gag proteins, and testing its requirements for function-
ing in virus budding.
RESULTS
Structural Studies of Human ALIX
As illustrated in Figure 1A, human ALIX can be subdivided
into three regions; the Bro1 domain (residues 1–358), the
‘‘V’’ domain (362–702), and the proline-rich region (PRR;
703–868). Constructs containing the PRR did not express
well in E. coli, but constructs spanning the Bro1 and V
domains could be expressed and purified. A series of
ALIXBro1-V proteins with loop mutations were surveyed to
identify a protein that would crystallize. The KK268,269YY
mutation enabled crystallization (apparently because
Tyr268 makes an important crystal contact), and the
structure of this protein (hereafter termed ALIXBro1-V)
was determined at a resolution of 3.3 A˚ (Rfree = 31.7%; Fig-
ures 1B and S1; Table S1). Isolated wild-type Bro1 and V
domains were also crystallized and their structures were
determined at higher resolutions (2.55 A˚, Rfree = 27.4%
and 2.6 A˚, Rfree = 30.2%, respectively; see Figures 1C–
1E). The V-domain crystals contained two molecules in
the asymmetric unit, and the different structures therefore
provided three independent views of the ALIX V domain.
Global Architecture of ALIXBro1-V
As illustrated in Figure 1B, the ALIXBro1-V protein adopts an
extended conformation in which the Bro1 and V domains842 Cell 128, 841–852, March 9, 2007 ª2007 Elsevier Inc.form discrete elements. Like its yeast analog, Bro1p (Kim
et al., 2005), ALIXBro1 is shaped like a banana, with a long
dimension of 100 A˚. The domain is organized about
a core tetratricopeptide repeat (TPR) composed of three
helical hairpins that associate into a right-handed super-
helix (Figure 1C). The ALIX V domain is composed of two
extended arms that fold back on themselves at an angle
of 30 to form a V. The arms are 77 A˚ (arm1) and 90 A˚
(arm2) in length, and each is organized about an extended
three-helix bundle (Figures 1D and 1E). The V-shaped
conformation brings the N-terminal Bro1 domain and the
C-terminal PRR (not present in the structure) into spatial
proximity, thereby explaining how Src kinase can simulta-
neously dock to the Bro1 domain and phosphorylate Tyr
residues in the ALIX C-terminal tail (Schmidt et al., 2005).
ALIXBro1-V has a highly asymmetric shape because the
long axes of the Bro1 and arm1 elements connect in par-
allel. As a result, ALIXBro1-V is 150 A˚ in its longest dimen-
sion but less than 50 A˚ in its other two. Small-angle X-ray
scattering profiles fit the crystal model well (R.D.F. and H.
Tsuruta, unpublished data), which indicates that the crys-
tal structure provides a good model for the solution struc-
ture of the uncomplexed protein. Nevertheless, we spec-
ulate that the different domains could change their relative
orientations in response to environmental cues like ligand
binding because the Bro1 and V domains are connected
by a single tripeptide linker (359VPV361) that makes only
limited noncovalent contacts (Figures 1B and 2A). More-
over, the V-domain arm trajectories vary in the three differ-
ent structures, which results in relative displacements of
up to 10 A˚ at their tips (Figure 2B). Finally, the loop region
between the two arms of the V domain also has the poten-
tial to act as a hinge (Figure 2C and Discussion). Thus, the
overall impression is that ALIXBro1-V is a scaffold com-
posed of extended domains that may reorient in response
to ligand binding.
Structure of the Bro1 Domain
The three helical hairpins that comprise the ALIXBro1 TPR
core (a4/5, a6/7, and a8/9) are each 50 residues in
length. They form a right-handed solenoid with a rotation
of 20 between each helical pair. The core is flanked
on one side by a10 (left in Figure 1C) and on the other by
a small b sheet (b1, b2) and a three-helix bundle (a1–3).
Both the N and C termini adopt extended conformations
that traverse opposite sides of the domain, with the first
17 residues extending along the convex surface and the
final 43 residues extending across the concave surface.
As expected, human ALIXBro1 generally resembles its
yeast counterpart (Kim et al., 2005), with an overall rmsd
of 2.8 A˚ over 338 equivalent Ca positions (Figure S2).
The character of the domain surface is also largely con-
served, with two exposed hydrophobic patches centered
about Tyr319 and Phe199. The first patch forms the dock-
ing site for Src kinase when Tyr319 is phosphorylated
(Schmidt et al., 2005), and the second patch forms the
binding site for the CHMP4B subunits of the ESCRT-III
complex (Kim et al., 2005 and see below). A strongly
Figure 1. Structure of ALIXBro1-V
(A) shows domain structure of human ALIX. Se-
quences that compose the different elements
are color coded here (and throughout) as fol-
lows: Bro1, turquoise; Bro1-V linker, brown;
V-domain arm1, green; V-domain loop,
salmon; V-domain arm2, blue; and Proline-
rich region (PRR), gray.
(B) Ribbon representation of ALIXBro1-V is
shown. Residues implicated in CHMP4 binding
(Ile212; yellow) or YPXnL binding (Phe495,
Val498, Ala509, Phe676, Leu680, and Ile683;
red) are highlighted. The Bro1 and V domains
are connected by a short hydrophobic linker
(359VPV361). The limited set of interdomain hy-
drophobic packing interactions is made by
Phe24 (a1, Bro1), Val359, Pro360, Val361,
Val363 (a11, arm1, and V), and Leu585 (a19,
arm1, and V).
(C) This ribbon diagram of ALIXBro1 shows the
secondary-structure-labeling scheme. The
view is from the underside of the orientation
shown in (A).
(D) shows a ribbon diagram of ALIXV showing
the secondary-structure-labeling scheme. As
compared to (A), this orientation is rotated
clockwise by 60 relative to a line perpendic-
ular to the plane of the paper.
(E) This surface rendering shows ALIXV se-
quence conservation. ALIXV sequences from
seven divergent species were aligned using
ESPript (Gouet et al., 1999); residues with
scaled similarity scores are color coded as fol-
lows: 85–100 are red, 68–84 are orange, and
50–67 are yellow.electropositive patch at one end of the yeast Bro1 domain
is also basic in the human protein, albeit to a lesser extent.
The human and yeast Bro1 domains differ most at one
end of the domain (right in Figure 1C), where N- and C-ter-
minal elements differ in secondary structure and packing
(Figure S2). Specifically, the C terminus of yeast Bro1p
forms three consecutive helical segments that cross the
concave side and then turn up into the domain, whereas
the equivalent residues in the human protein (342–358)
form an extended strand that traverses a similar path but
terminates earlier. Thus, the C-terminal helix of the yeast
protein packs between a3 and the a1–2 hairpin (ALIXBro1
numbering), whereas the human Bro1 C terminus isshifted by 10 A˚, and the first three helices of human
ALIXBro1 collapse into a three-helix bundle (a maximal rel-
ative shift of12 A˚). It appears possible that these distinct
C-terminal conformations could alter the relative orienta-
tions of the Bro1 and V domains in the different proteins.
The Structure of the ALIX V Domain
Both arms of the ALIX V domain are composed of ex-
tended three-helix bundles, although a series of short
breaks subdivide the major helices into 11 different seg-
ments (Figures 1D, S1, and S3). The topology of the V do-
main is notable in that the polypeptide chain crosses the
arm1/arm2 ‘‘loop’’ region three times in the course ofCell 128, 841–852, March 9, 2007 ª2007 Elsevier Inc. 843
Figure 2. Interdomain Linkers and Con-
formational Flexibility of ALIXBro1-V
(A) Stereoview showing the linker between the
Bro1 and V domains is shown. Secondary
structures are color coded as in Figure 1B,
and residues that contact the 359VPV361 linker
are shown explicitly.
(B) This stereoview illustrates conformational
variability in different V-domain structures.
The different trajectories of arm2 were visual-
ized by superimposing only the arm1 regions
from crystals of ALIXBro1-V (salmon) and from
the two different molecules in the ALIXV asym-
metric unit (green and blue). The only other sig-
nificant difference between the structures was
in the position of Trp476 residue (a4/5 loop),
which flips out of the core of arm2 in one of
the two ALIXV structures to make a crystal
contact.
(C) shows a stereoview illustrating the three-
stranded loop region that connects the two
arms of the V domain. Secondary structures
are color coded as in Figure 1B. Side chains
within the loop and adjacent residues are
shown, and the stabilizing interactions of the
Arg649 residue are shown explicitly. The purple
cage denotes a pocket that appears to be
occupied by a mix of ordered and disor-
dered water molecules. The view is from the
bottom of (B).building the two helical bundles (Figure S3). Hence, the
two arms are highly interconnected in primary sequence,
and the entire V domain likely represents a single func-
tional entity.
The two V-domain arms are primarily stabilized by hy-
drophobic side-chain-packing interactions that are based
upon heptad repeats and that adopt canonical ‘‘knobs
into holes’’ side-chain packing. This explains why the do-
main scored highly in coiled-coil prediction algorithms
(Katoh et al., 2003; Odorizzi et al., 2003). In contrast, the
three strands in the loops connecting arm1 and arm2 are
stabilized almost exclusively by hydrophilic interactions,
most of which are mediated by backbone atoms. An illus-
trative example is provided by the highly conserved
Arg649 residue (a21, arm2), which forms a series of inter-
actions that buttress the underside of the loop region;
these include a buried salt bridge with Asp407 (a12/13
loop) and hydrogen-bonding interactions with a buried844 Cell 128, 841–852, March 9, 2007 ª2007 Elsevier Inc.water molecule and with the backbone carbonyl oxygen
atoms of Pro535 (a17/18 loop) and Thr412 (a12/13 loop).
The loop region also encloses a hydrophilic interior cavity
of 67 A˚3 (purple in Figure 2C).
The V domain exhibits intrinsic conformational flexibil-
ity, as revealed by comparisons of the relative positions
of the two arms in the different crystal structures. Isolated
arm1 structures from the crystallographically independent
models overlap well (rmsd = 1.4 A˚), and the same is true for
the arm2 structures, but overlapping on either arm causes
the other to ‘‘fan out’’ into different positions. This is illus-
trated in Figure 2B for the case of overlap on arm1, where
the relative arm2 displacements reach up to 10 A˚ at their
distal ends. These global differences in the structures
arise from small, cumulative changes in the interhelical
packing interactions along both arms rather than from
a dramatic reorganization of the loop region or elsewhere.
Thus, the structures demonstrate that the V-domain arm
Figure 3. Identification of the YPXnL-Binding Site on ALIXV
(A) Biosensor binding isotherms for purified HIV-1 p6Gag and EIAV p9Gag constructs binding to immobilized ALIXV domain constructs are shown.
(B) YPXnL-binding site on ALIXV arm2 is shown here as viewed from arm1. Residue conservation is color coded as in Figure 1E. Underlined residues
were mutated and tested for YPXnL-binding activity and/or for activity in the HIV-1 DPTAP rescue assay (see text).positions can vary, although the biological significance of
this observation remains to be elucidated.
The ALIX VDomain Binds HIV-1 p6Gag and EIAV p9Gag
YPXnL Late Domains
ALIX binds and facilitates budding of retroviral Gag pro-
teins that contain YPXnL late domains, but the interaction
site is not yet known. We therefore performed biosensor
binding experiments to map the YPXnL-binding site and
measure the binding affinities of the HIV-1 p6Gag and
EIAV p9Gag proteins. As shown in Figure 3A, the immobi-
lized ALIX V domain bound both HIV-1 p6Gag and EIAV
p9Gag, with dissociation constants of 59 ± 15 mM and
1.2 ± 0.3 mM, respectively. In both cases, binding was
specific for the YPXnL late domain because YP to SR
mutations (termed DYP; Strack et al., 2003) reduced bind-
ing affinities substantially (>15-fold). Very similar binding
data were also obtained for the ALIXBro1-V construct, which
indicates that the Bro1 domain did not contribute to the
binding interaction (Table S2).
Close inspection of the V-domain surface revealed
a highly conserved hydrophobic groove on arm2 between
helices 16 and 21, centered about Phe676, that was
a strong candidate for the YPXnL late-domain-binding
site (Figures 1D, 1E, 3B, and S4). This site is exposed to
solvent but is located near the base of the V, where the
two arms are separated by only 5–10 A˚. Phe676 sits at
one end of a deep pocket (10 A˚) that is lined by a series
of highly conserved residues (highlighted in red in
Figure 3B). A shallower hydrophobic groove also extends
7 A˚ above Phe676, although the residues that line thishalf of the site are less well conserved (Figures 3B, S1,
and S4).
Mutational analyses confirmed that a series of con-
served residues within the putative YPXnL-binding site
on arm2 were required for full-affinity HIV-1 p6Gag and
EIAV p9Gag binding. As shown in Figure 3A, the
Phe676Asp mutation abolished any detectable binding
to either HIV-1 p6Gag or EIAV p9Gag, which represents
a >1000-fold reduction in EIAV p9Gag binding affinity. Mu-
tations in two other binding-groove residues (Val498Asp
and Ile683Asp) also reduced HIV-1 p6Gag and EIAV
p9Gag binding affinities substantially (R20 fold; see Table
S2). These data indicate that retroviral Gag YPXnL late
domains bind the V domain of ALIX at a conserved site
that spans the side and interior face of arm2.
Requirements for ALIX in EIAV and HIV-1 Release
Previous studies have indicated that ALIX can function in
the release of both EIAV and HIV-1 (Chen et al., 2005; Mar-
tin-Serrano et al., 2003; Strack et al., 2003; von Schwedler
et al., 2003). Importantly, however, EIAV p9Gag contains
a single known late domain (the 23YPDL26-ALIX site),
whereas HIV-1 p6Gag contains two late domains: a
7PTAP10-TSG101 site and a 36YPLASL41-ALIX site. We
therefore assessed the relative importance of ALIX for
the release of both EIAV and HIV-1. As shown in Figure 4A,
the release of virion-associated Gag-derived CA protein
from HeLa cells expressing a wild-type EIAV vector was
readily detected in western blot assays (lane 1, upper
panel), but the DYP mutation in the p9Gag ALIX-binding
site reduced EIAV particle release 12-fold (compare lanes
1 and 2, panel 1). ALIX depletion similarly reduced theCell 128, 841–852, March 9, 2007 ª2007 Elsevier Inc. 845
Figure 4. Requirement for ALIX in EIAV and HIV-1 Budding
(A) ALIX requirements for EIAV vector budding are shown as follows:
lanes 1, wild-type (WT) EIAV vector expressed in wild-type HeLa cells
(positive control); lanes 2, EIAV vector encoding a 23SR24 mutation in
the 23YPDL26 late domain of p9
Gag (DYP) expressed in wild-type
HeLa cells; and lanes 3, wild-type EIAV vector expressed in cells de-
pleted of ALIX using shRNA. Western blots are shown as follows: panel
1, virus-like particle (VLP) production (anti-CA antibody) reports the
amount of successful budding and panel 2, cellular Gag protein levels
(anti-CA antibody) control for expression. Note that CA corresponds to
the processed central domain of Gag, p55 corresponds to full-length
Gag protein, and p40 and p47 are intermediate Gag cleavage prod-
ucts. Cellular Gag levels were similar in all cases, although the pro-
cessing was somewhat delayed in the DYP mutant and in the absence
of ALIX. Panel 3 shows cellular ALIX levels (anti-ALIX antibody).
(B) The relative importance of ALIX and TSG101 binding for HIV-1 virus
budding is shown. Lanes 1 show wild-type (WT) HIV-1 expressed in
293T cells (positive control), lanes 2 show HIV-1 encoding a 36SR37
mutation in the 36YPLASL41 late domain of p6
Gag (DYP), and lanes 3
show wild-type HIV-1 encoding a 7LIRL10 mutation in the 7PTAP10
late domain of p6Gag (DPTAP). Western blots show virus production
(panel 1) and cellular Gag protein levels (panel 2, anti-CA and anti-
MA antibodies; MA is the processed N-terminal domain of Gag). Panel
3 shows viral titers measured in a single-cycle MAGIC assay (errors are
standard deviations from three separate infectivity experiments). Note846 Cell 128, 841–852, March 9, 2007 ª2007 Elsevier Inc.release of wild-type EIAV 10-fold (compare lanes 1 and 3,
upper panel). shRNA depletion of ALIX from HeLa cells
was very efficient (lane 3, bottom panel), and EIAV Gag ex-
pression was not significantly affected by either the p9Gag
DYP mutation or by ALIX depletion (middle panels). Gag
processing was inhibited slightly, however, which is rem-
iniscent of the Gag-processing delay observed upon inhi-
bition of HIV-1 budding (Gottlinger et al., 1991). We there-
fore conclude that the 23YPDL26-ALIX interaction plays
a critical role in enhancing EIAV Gag release, which is in
good agreement with previous studies (Martin-Serrano
et al., 2003; Puffer et al., 1997; Strack et al., 2003).
The importance of ALIX for HIV-1 release was also
tested by measuring the effect of the DYP mutation in
the ALIX-binding site of HIV-1 p6Gag. As shown in
Figure 4B, this mutation reduced HIV-1 Gag release from
293T cells, as measured in both a western blot assay
(compare lanes 1 and 2, panel 1) and by viral titers in a sin-
gle-cycle MAGIC infectivity assay (lanes 1 and 2, panel 3).
However, the reductions in release and infectivity were
modest (3-fold). In comparison, a mutation that blocked
the 7PTAP10-TSG101 interaction (PTAP7-10LIRL, termed
DPTAP) had a much more profound effect on HIV-1 release
and reduced infectious titers more than 100-fold
(Figure 4B, compare lanes 1 and 3). Neither late-domain
mutation affected Gag protein expression, although both
again delayed Gag processing, as evidenced by intracellu-
lar accumulation of the CA-SP1-processing intermediate,
with the more profound effect again seen for the DPTAP
mutation (Figure 4B, central panel). These experiments in-
dicate that ALIX and TSG101 both enhance the release of
wild-type HIV-1 from 293T cells but that the virus depends
much more heavily upon the 7PTAP10-TSG101 interaction.
These studies again generally agree well with previous mu-
tational analyses that utilized different HIV-1 constructs
and cell types and were performed before the discovery
of the p6Gag 36YPLASL41-ALIX interaction (Demirov et al.,
2002; Gottlinger et al., 1991; Huang et al., 1995).
ALIX Overexpression Rescues Release
and Infectivity of HIV-1 DPTAP
The experiments described above demonstrate that the
p9Gag 23YPDL26-ALIX late-domain interaction plays a ma-
jor role in facilitating EIAV release, yet the p6Gag
36YPLASL41-ALIX interaction does not efficiently substi-
tute for the 7PTAP10-TSG101 interaction in supporting
HIV-1 release. We hypothesized that this apparent dis-
crepancy might reflect a reduced ability of HIV-1 to recruit
ALIX owing to the lower affinity of the p6Gag YPXnL-bind-
ing site. We therefore tested whether the inefficient re-
lease of the HIV-1 DPTAP virus from 293T cells could be
‘‘rescued’’ by increasing intracellular ALIX concentrations.
that cellular CA and MA levels were similar in all cases but that the
CA-SP1-processing intermediate accumulated in the DYP and DPTAP
constructs, which is a typical diagnostic of virus-budding inhibition.
As shown in Figure 5, HIV-1 DPTAP release and infectivity
were indeed stimulated very dramatically (25-fold) by
ALIX overexpression (Figure 5, panels 1 and 4, compare
lanes 1 and 2). Hence, raising cellular ALIX levels could re-
store HIV-1 DPTAP infectivity to within 20% of the wild-
type virus. Importantly, ALIX overexpression did not alter
intracellular Gag expression or processing (panel 2), which
demonstrates that the enhancement occurred at late
stages in particle assembly or budding. Control experi-
ments also confirmed that the p6Gag 36YPLASL41-ALIX in-
teraction was responsible for this enhancement because
ALIX overexpression did not stimulate the release of an
HIV-1 DPTAP virus that also lacked a functional ALIX-
binding site (compare lanes 2 and 4). Indeed, the second-
ary DYP mutation actually reduced HIV-1 DPTAP release
and infectivity by an additional 5-fold (compare lanes
3 and 4 to lane 1) presumably because the mutation also
inhibited the ability of endogenous ALIX to mediate low-
level release. These experiments demonstrate that ALIX
can replace TSG101 in its role of supporting the efficient
release of infectious HIV-1, provided ALIX is present at
sufficient levels to overcome the modest affinity of the
36YPLASL41-ALIX interaction.
ALIX YPXnL-Binding Activity Is Required
for Virus Release
The rescue of HIV-1 DPTAP release and infectivity upon
ALIX overexpression provided a convenient assay for test-
ing which ALIX activities were required for functional virus
release. This assay was initially used to test whether ALIX
mutations that inhibited YPXnL binding in vitro also
inhibited virus release through the ALIX pathway. As
described previously, overexpression of wild-type ALIX
enhanced the release and infectivity of HIV-1 DPTAP
25-fold (Figure 6A, compare lanes 1 and 2). In contrast,
ALIX proteins with point mutations that inhibited YPXnL
binding (Val498Asp, Phe676Asp, and Ile683Asp) failed to
rescue HIV-1 DPTAP release or infectivity (compare lanes
2 and 3–5). These mutations did not affect ALIX expres-
sion or stability (panel 3), nor did they affect cellular Gag
levels (panel 2). Similar data were obtained for a series
of other mutations within the YPXnL-binding site
(Phe495Asp, Val509Asp, and Leu680Asp), whereas muta-
tions in a second conserved hydrophobic patch located
on arm1 (Leu401Asp, Ile405Asp, and Leu556Asp) did
not diminish ALIX rescue significantly (<2-fold, data not
shown). These data reinforce the idea that ALIX binds
YPXnL late domains within the site shown in Figure 2B
and demonstrate that ALIX mutations that impair YPXnL
binding also inhibit virus release and infectivity.
ALIX Recruitment of CHMP4/ESCRT-III Is Required
for HIV-1 DPTAP Release
In addition to binding YPXnL late domains, ALIX also binds
CHMP4/ESCRT-III proteins through the Bro1 domain,
suggesting that ALIX may serve to connect retroviral
Gag proteins to the ESCRT-III machinery (Katoh et al.,
2003; Kim et al., 2005; Martin-Serrano et al., 2003; Odor-izzi et al., 2003; Strack et al., 2003; von Schwedler et al.,
2003). We therefore tested whether the interaction be-
tween ALIX and CHMP4A was required for virus budding.
Previous work showed that mutations in an exposed hy-
drophobic patch on yeast Bro1p inhibited Snf7p
(CHMP4) binding and prevented proper MVB sorting
(Kim et al., 2005). We found that a mutation within the
equivalent patch on human ALIX, Ile212Asp, similarly in-
hibited the ALIXBro1-CHMP4A interaction, as assayed in
a GST pulldown experiment (Figure 6B). As expected,
wild-type ALIXBro1 bound to a GST-CHMP4A fusion pro-
tein but not to GST alone (compare lanes 2 and 3). In con-
trast, the ALIXBro1,I212D mutant did not bind GST-CHMP4A
detectably (compare lanes 3 and 6).
Figure 5. ALIX Overexpression Rescues HIV-1 DPTAP
Release and Infectivity
Virus release, cellular Gag protein levels, exogenous ALIX expression,
and viral infectivity are shown as analyzed by western blotting (panels
1–3) or MAGIC infectivity assays (panel 4). Lanes 1 show HIV-1 DPTAP
cotransfected with an empty pCI-neo vector control, lanes 2 show HIV-
1 DPTAP cotransfected with a vector expressing FLAG-ALIX, lanes 3
show HIV-1 DPTAP DYP cotransfected with an empty vector control,
and lanes 4 show HIV-1 DPTAP DYP cotransfected with a vector
expressing FLAG-ALIX. For reference, wild-type HIV-1 titers were
typically 65,000 IU/50 ml, and overexpression raised ALIX levels
50-fold over endogenous protein levels as estimated by western
blotting with anti-ALIX antibodies (not shown). Error bars in infectivity
assays represent standard deviations of three separate infectivity
experiments.Cell 128, 841–852, March 9, 2007 ª2007 Elsevier Inc. 847
Figure 6. ALIX Mutants Lacking YPXnL-
and CHMP4-Binding Activities Do
Not Support HIV-1 DPTAP Release and
Infectivity
(A) HIV-1 DPTAP release and infectivity when
coexpressed with an empty vector (; lanes
1), with vectors expressing wild-type ALIX
(lanes 2), or with ALIX mutants defective in
YPXnL binding (lanes 3–5) are shown. ALIX
and Gag protein levels were analyzed by west-
ern blotting (panels 1–3), and infectious titers
were analyzed using MAGIC assays (panel 4).
(B) This GST pulldown assay shows that the
ALIXBro1 mutation Ile212Asp inhibits GST-
CHMP4A binding. Binding experiments were
performed with wild-type ALIXBro1 (lanes 1–3)
and the I212D mutant (lanes 4–6). Lanes 1 and
4 show pure ALIXBro1 proteins (reference
markers), lanes 2 and 4 show ALIXBro1 proteins
binding to GST alone (negative controls), and
lanes 3 and 6 show ALIXBro1 proteins binding
to GST-CHMP4A.
(C) HIV-1 DPTAP release and infectivity are
shown when coexpressed with an empty ex-
pression vector (, lanes 1), with vectors ex-
pressing wild-type ALIX (lanes 2), or with the
ALIX Ile212Asp mutant (lanes 3), which is de-
fective in CHMP4A binding. In (A) and (C),
HIV-1 DPTAP release, cellular Gag protein
levels, exogenous ALIX expression, and viral
infectivity were analyzed as described in
Figure 4, with error bars representing standard
deviations from three separate infectivity
experiments.We next tested whether the Ile212Asp mutation af-
fected the ability of ALIX to rescue HIV-1 DPTAP infectiv-
ity. As shown in Figure 6C, the ALIXI212D mutant expressed
well (panel 3, compare lanes 2 and 3) but failed to rescue
HIV-1 DPTAP release or infectivity significantly (top and
bottom panels, compare lanes 2 and 3). Hence, the
Ile212Asp mutation strongly inhibited the ability of ALIX
to support HIV-1 release, implying that one essential
ALIX function in virus budding is to recruit CHMP4/
ESCRT-III.
Other ALIX Functions in Virus Budding
The HIV-1 DPTAP rescue assay was also used to survey
the functional importance of four other known ALIX proper-
ties: Tyr319 phosphorylation, TSG101 binding, endophilin
binding, and interactions of the C-terminal PRR. ALIX mu-
tants defective in each of these properties were generated
and tested for their ability to rescue HIV-1 DPTAP release.
In the first case, the ALIX Tyr319Phe mutation, which848 Cell 128, 841–852, March 9, 2007 ª2007 Elsevier Inc.blocks phosphorylation and Src kinase binding (Schmidt
et al., 2005), did not impair the rescue of HIV-1 DPTAP re-
lease and infectivity (Figure 7, lane 3). This result indicates
that Src binding and phosphorylation do not play essential
(or nonredundant) roles in ALIX virus-budding activity.
ALIX can also bind directly to the N-terminal UEV do-
main of TSG101 via a 717PSAP720 motif located in the
ALIX PRR (Martin-Serrano et al., 2003; Strack et al.,
2003; von Schwedler et al., 2003). This interaction is of in-
terest because it provides a potential mechanism for as-
sociation of the two known late-domain-binding partners
of HIV-1. As expected, mutation of the final proline in the
717PSAP720 motif (Pro720Leu) eliminated TSG101 UEV
binding entirely (Figure S5A). However, the ALIXP720L mu-
tant fully rescued HIV-1DPTAP release and infectivity (Fig-
ure 7, lane 4), which indicates that a functional TSG101-
binding site was not required for ALIX to support virus
budding. Indeed, we found that ALIX overexpression
rescued HIV-1 DPTAP release even when TSG101 was
depleted from cells (not shown), which indicates that the
ALIX and TSG101 virus-budding pathways can function
independently.
Endophilins represent another interesting class of ALIX-
binding partners because endophilins can bind mem-
branes and can drive (or sense) membrane curvature.
Moreover, endophilin-2 binds and facilitates MLV Gag
protein release (Wang et al., 2003). Endophilins bind the
755PXRPPPP761 sequence within the ALIX PRR (Chatel-
lard-Causse et al., 2002; Shibata et al., 2004). We em-
ployed yeast two-hybrid assays to confirm that the ALIX
RP757,758AA mutation inhibited binding to both endophi-
lin-1 and -2 (Figure S5B). Despite lacking endophilin-bind-
ing activity, however, the ALIXRP757,758AA mutant effi-
ciently rescued HIV-1 DPTAP release and infectivity,
which indicates that endophilin binding was also dispens-
Figure 7. ALIX Requirements for HIV-1 DPTAP Release and
Infectivity
HIV-1 DPTAP release and infectivity are shown when coexpressed
with: an empty vector (; lanes 1) with expression vectors for wild-
type ALIX (lanes 2), with the ALIX Y319F mutant (lanes 3), which cannot
be phosphorylated on residue 319, with the ALIXP720L mutant (lanes 4),
which is defective in TSG101 binding, with the ALIXRP757,758AA mutant
(lanes 5), which is defective in endophilin binding, or with the ALIXD831–
868 mutant (lanes 6), which lacks the final 38 residues in the PRR. HIV-1
DPTAP release, cellular Gag protein levels, exogenous ALIX expres-
sion, and viral infectivity were analyzed as described in Figure 4, with
error bars representing standard deviations from three separate infec-
tivity experiments.able for the virus-budding function of ALIX (Figure 7,
lane 5).
Finally, we tested the general importance of the ALIX
PRR using several deletion mutants, the shortest of which
removed just the final 38 ALIX residues (ALIXD831–868). All
of the C-terminal deletion mutants tested, including
ALIXD831–868, failed to rescue HIV DPTAP release and in-
fectivity (lane 6) despite equivalent expression levels of
the mutant and wild-type proteins (panel 3, compare lanes
2 and 6). We therefore conclude that ALIX PRR interac-
tion(s) are required for late budding activity.
DISCUSSION
ALIXBro1-V Structure
The elongated Bro1 domain extends from the first arm of
the central V domain, which gives ALIXBro1-V the shape
of a ‘‘check mark.’’ This distinctive conformation explains
how Src kinase can bridge the N-terminal Bro1 domain
and the distal PRR tail and how it may similarly bring other
Bro1- and PRR-binding proteins into close proximity. The
ALIXBro1-V structure also suggests several ways in which
conformational changes could function in the numerous
biological roles ascribed to ALIX. Two types of domain
motion are attractive possibilities: (1) variation in the rela-
tive orientation of the Bro1 and V domains, which appears
possible given the limited number of contacts made by the
interdomain linker (Figure 2A), and (2) variation in the tra-
jectories of the two arms of the V domain, as implied by
differences in the three different V-domain structures
(Figure 2B).
In addition to the modest variation in arm orientation ob-
served between crystal structures, we speculate that the V
domain might function as a ‘‘molecular hinge,’’ with the
structures reported here corresponding to the closed con-
formation. This idea is consistent with the lack of hydro-
phobic packing interactions throughout the loop region
of the V domain (Figure 2C). The hydrophilic loop-packing
interactions that do exist are well defined and geometri-
cally constrained, however, which indicates that if the
loop functions as a hinge, then activation energy will be re-
quired to break these interactions and open the V. In prin-
ciple, hinge opening could be driven by posttranslational
modifications and/or ligand binding and might expose
new binding sites and thereby provide an elegant mecha-
nism for transmitting signals for complex assembly and
disassembly. YPXnL late domains are obvious candidates
for triggering a possible hinge-opening motion because
they bind near the base of the V at a site located nearly be-
tween the two arms.
YPXnL Binding
We have mapped the YPXnL-binding site to a conserved,
hydrophobic groove on arm2 of the ALIX V domain and
demonstrated that YPXnL binding is required for ALIX-me-
diated budding of both HIV-1 and EIAV. ALIX binds nearly
603more tightly to EIAV p9Gag than to HIV-1 p6Gag, which
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domain is an optimized ALIX-binding site (Vincent
et al., 2003). This presumably reflects the fact that EIAV
contains just a single known late domain and therefore
relies heavily on ALIX to bud from cells. In contrast, the
weaker HIV-1 36YPLASL41-ALIX late-domain interaction
implies that suboptimal binding must confer a selective
advantage when a functional TSG101-binding site is also
present. This same trend can be seen in many different SIV
strains, where the absence of a TSG101-binding site
appears to correlate with the presence of an optimized
ALIX-binding site (and vice versa; Bibollet-Ruche et al.,
2004). Hence, viral late domains are not necessarily opti-
mized for high-affinity binding, particularly when a virus
employs multiple late domains.
We also found that ALIX can efficiently support the re-
lease and infectivity of an HIV-1 construct that lacks
a TSG101-binding site, provided that the cellular ALIX
levels are high enough to overcome the relatively weak
binding affinity. Importantly, virus release via ALIX does
not require TSG101, and vice versa. Similarly, TSG101 is
not required for release of a Dp6 HIV-1 chimera that
buds via a fused EIAV p9Gag element (Martin-Serrano
et al., 2003) nor for ALIX stimulation of murine leukemia vi-
rus budding (Segura-Morales et al., 2005). These observa-
tions all indicate that although TSG101 and ALIX can bind
one another and function together in the MVB pathway,
they represent independent routes out of the cell. The de-
cisions as to which late domain(s) are employed by a par-
ticular virus, how many late domains are used, and the af-
finity of each binding site presumably reflect a complex
optimization of the different possible exit routes from rele-
vant host cell types.
Although the precise mechanistic role of the different
cellular Class E proteins in enveloped virus budding is
not yet clear, there is increasing evidence that viruses
may be mimicking cellular interactions that allow mem-
brane proteins to recruit the MVB machinery and be
sorted into MVB vesicles, which ultimately leads to lyso-
somal degradation or release within extracellular exo-
somes. Interestingly, both the AP-2 adaptor complex
and ALIX can bind a Tyr-based motif found in the cyto-
plasmic tail of the transferrin receptor (TR; although the
motif does not match the YPXnL consensus; Geminard
et al., 2004). Vidal and colleagues have argued that the
AP-2 interaction directs TR endocytosis, and the ALIX in-
teraction may then direct the TR into exosomes that are
released by maturing reticulocyte cells (Geminard et al.,
2004). Both AP-2 and ALIX also bind the EIAV p9Gag late
domain and function in virus release (Chen et al., 2005),
which suggests that EIAV may bud via the same pathway
that sorts cellular TRs into reticulocyte-derived exosomes.
To date, the only well-documented example in which an
ALIX-like protein binds a nonviral YPXnL motif is for an
ALIX homolog in Aspergillus nidulans, PalA, which binds
tandem YPXL/I tetrapeptide repeats within PacC, a protein
involved in sensing and responding to pH changes
(Vincent et al., 2003). The YPXL/I motifs are required for
pH-dependent proteolytic activation of PacC, although850 Cell 128, 841–852, March 9, 2007 ª2007 Elsevier Inc.the precise role of PalA in this process is not clear.
Other cellular binding partners for the ALIX V domain pre-
sumably exist, but the lack of a strong consensus se-
quence for the YPXnL-like binding motifs complicates their
identification.
Other Functional Requirements
Our studies also show that one essential function of ALIX
in virus budding is to recruit the CHMP4/ESCRT-III com-
plex. It has been challenging to establish a direct role for
the ESCRT-III proteins in virus budding because human
cells express 11 distinct, but related, ESCRT-III subunits,
and it is therefore difficult to differentiate between nones-
sential versus redundant functions (e.g., see Langelier
et al., 2006). Our work provides the most direct demon-
stration to date that ESCRT-III recruitment is required for
virus budding and is consistent with previous studies
showing that dominant-negative ESCRT-III constructs
can block virus release (Martin-Serrano et al., 2003;
Strack et al., 2003; von Schwedler et al., 2003) and that ar-
tificial Gag fusions that recruit ESCRT-III subunits can
substitute for the 23YPDL26 late domain in supporting
EIAV p9Gag release (Pineda-Molina et al., 2006). Hence,
there is now increasing evidence that while enveloped
RNA viruses can enter into the MVB pathway via many dif-
ferent binding partners, they ultimately require access to
the ESCRT-III and VPS4-LIP5 complexes, which appear
to be the functional machinery of MVB protein sorting/
vesicle formation.
The PRR of ALIX also provides essential function(s) in vi-
rus budding. While the terminal 38 residues of ALIX could
play a structural role, the high Pro and Gln content of this
region (34% and 24%, respectively) makes it more likely
that the polypeptide is inherently unstructured and can
adopt an extended conformation that serves as the dock-
ing site for other cellular proteins. We have shown that en-
dophilin and TSG101 binding to the PRR appear to be dis-
pensable (or redundant) for viral budding. Determining the
subset of PRR interactions that are essential for virus bud-
ding will likely shed light on the mechanistic requirements
for protein sorting/vesicle formation and will further reveal
how ALIX can serve as an adaptable, multidomain scaffold
that links retroviral Gag proteins to essential cellular
budding machinery.
EXPERIMENTAL PROCEDURES
Summary of Protein Expression, Purification,
and Structure Determination
For protein-interaction studies, HIV-1 p6Gag and EIAV p9Gag were ex-
pressed as GST fusions in E. coli and purified by affinity chromatogra-
phy and gel filtration chromatography (following protolytic removal of
GST). ALIXBro1-V, ALIXBro1, and SeMet ALIXV were similarly expressed
as GST or 63-His N-terminal fusion proteins in E. coli and affinity pu-
rified for binding studies and crystallization. The 6x-His tag was left on
crystallized ALIXBro1 but removed from ALIXBro1-V and ALIXV. The crys-
tallized ALIXBro1-V protein had a KK268,269YY mutation. Structures were
determined by SAD (ALIXV) or molecular replacement (ALIXBro1 and
ALIXBro1-V) and refined as summarized in Table S1. Full details of
plasmid construction, protein expression, crystallization, and structure
determination are provided in the Supplemental Data.
Protein-Protein Interaction Experiments
Biosensor binding experiments were performed as described (Garrus
et al., 2001) with purified HIV-1 p6Gag, EIAV p9Gag, and HIV-1
TSG101UEV proteins binding to immobilized GST-ALIXBro1-V, GST-
ALIXV, GST-ALIXBro1, and GST-ALIX714–723 proteins. Assay conditions
and binding affinities are provided in Table S2. GST pulldown experi-
ments were performed as described (von Schwedler et al., 2003) using
purified ALIXBro1 proteins binding to GST or GST-CHMP4A proteins
captured from clarified E. coli lysates.
Assays for HIV-1 DPTAP Release and Infectivity
293T cells (83 105 cells/well in 6-well plates) were transfected with 1
mg of HIV-1 DPTAP plasmid (Garrus et al., 2001) + 1 mg of ALIX expres-
sion vector per well (10 ml Lipofectamine 2000, Invitrogen). Cytoplas-
mic proteins and sucrose-pelleted virions were harvested 24 hr post-
transfection, analyzed by western blotting, and quantified using an
Odyssey imaging system (Li-COR, Inc.). Primary antibodies were rab-
bit anti-CA and rabbit anti-MA at 1:15,000. HIV-infectious titers were
assayed in single-cycle MAGIC assays in P4 cells. Additional experi-
mental details are provided in von Schwedler et al. (2003).
EIAV VLP Production and ALIX Silencing
HeLa M cells (4 3 105 cells/well, 6-well plate) were transiently trans-
fected (10 ml; FuGene6, Roche Applied Science) with 5 mg of wild-type
or p9Gag DYP pEV53B EIAV vector (Olsen, 1998). EIAV virus-like parti-
cles were harvested 48 hr posttransfection, concentrated through
20% sucrose cushions, and analyzed by western blotting using affin-
ity-purified EIAV anti-CA antibody (1:10,000). For ALIX-depletion ex-
periments, an shRNA targeting human ALIX nucleotides 1765–1783
(Chen et al., 2005) was delivered using the FG12 lentiviral expression
vector (Qin et al., 2003; 8 mg/ml polybrene, moi = 15) 24 hr prior to
transfection with pEV53B.
Supplemental Data
Supplemental Data include Experimental Procedures, References, five
figures, and two tables and can be found with this article online at
http://www.cell.com/cgi/content/full/128/5/841/DC1/.
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